Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: BIOCRYST PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-09-01 to 2022-09-30
Current total value of award: $2614651.55
Description: EXTEND PERIOD OF PERFORMANCE FOR THE BASE TILL SEPTEMBER 30, 2022. (NOTE: THE MODIFICATION P00003 IS MODIFICATION P00002 IN THE NBS SYSTEM, MODIFICATION P00004 IS MODIFICATION P00003 IN THE NBS SYSTEM AND THESE ARE CLARIFICATIONS FOR AUDIT PURPOSES